| 1 |
34679189 | Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. | 2022 Feb |
1 |
| 2 |
35304767 | Evaluation of adherence monitoring in buprenorphine treatment: A pilot study using timed drug assays to determine accuracy of testing. | 2022 Mar 18 |
1 |
| 3 |
33154520 | A review of the existing literature on buprenorphine pharmacogenomics. | 2021 Apr |
1 |
| 4 |
33750027 | Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route. | 2021 Sep |
5 |
| 5 |
34520028 | Buprenorphine not detected on urine drug screening in supervised treatment. | 2021 |
2 |
| 6 |
32585880 | Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. | 2020 Jun 23 |
1 |
| 7 |
29102550 | A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4. | 2018 Mar |
3 |
| 8 |
30167757 | Voriconazole greatly increases the exposure to oral buprenorphine. | 2018 Dec |
2 |
| 9 |
29450233 | Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach. | 2017 Dec |
1 |
| 10 |
28097004 | Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. | 2016 Dec |
1 |
| 11 |
22148986 | Is maternal opioid use hazardous to breast-fed infants? | 2012 Jan |
1 |
| 12 |
22845044 | Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. | 2012 Sep 1 |
1 |
| 13 |
21515002 | Gender differences in pharmacokinetics of maintenance dosed buprenorphine. | 2011 Nov 1 |
1 |
| 14 |
20829393 | Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells. | 2010 Dec |
3 |
| 15 |
18294936 | Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. | 2009 Jul |
1 |
| 16 |
17598095 | An in vitro approach to potential methadone metabolic-inhibition interactions. | 2007 Sep |
1 |
| 17 |
16507617 | Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. | 2006 Mar |
1 |
| 18 |
15966752 | Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. | 2005 |
1 |
| 19 |
15501692 | Methadone--metabolism, pharmacokinetics and interactions. | 2004 Dec |
1 |
| 20 |
12756210 | Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. | 2003 Jun |
3 |
| 21 |
12033517 | Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. | 2002 May |
1 |
| 22 |
10755464 | Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. | 2000 Feb 25 |
2 |
| 23 |
10873929 | Lack of interaction of buprenorphine with flunitrazepam metabolism. | 2000 Jul |
2 |
| 24 |
9565774 | In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. | 1998 |
1 |
| 25 |
9698298 | Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. | 1998 Aug |
1 |
| 26 |
9180349 | Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. | 1997 |
1 |